Axovant Sciences (AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix (ZGNX) and Amicus Therapeutics (FOLD).
Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.
About the Author Reprints
Are there any Clinical trials to help a past abused spouse facial under the rt. Appears sunken inward was choke so bad at one point when she speaks she sounds as if she has male voice it is embrassing for me